Vikas Sinha - Jul 28, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Officer Title: President and Chief Financial Officer, Director, 10%+ Owner
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Stock symbol
ALVR
Transactions as of
Jul 28, 2022
Transactions value $
$15,000,000
Form type
4
Date filed
8/1/2022, 04:38 PM
Previous filing
Jul 21, 2022
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $15M +3.25M +24.24% $4.61 16.7M Jul 28, 2022 By ElevateBio LLC F1, F2
holding ALVR Common Stock 938K Jul 28, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share.
F2 Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Officer Title: President and Chief Financial Officer